Distal and Total Pancreatectomy With En Bloc Celiac Axis Resection for Pancreatic Cancer at a High-Volume Center Authors: Carsten P. Hansen, Stefan K. Burgdorf, Jan H. Storkholm Published: 2026 ABSTRACT Objective:This study evaluated outcomes after distal and total pancreatectomy with en bloc celiac axis resection (DP-CAR/TP-CAR), and preoperative hepatic artery embolization intended to mitigate postoperative organ ischemia.Background:DP-CAR and TP-CAR are surgical interventions for advanced pancreatic cancer, associated with substantial complication and recurrence rates. Despite advancements in oncologic therapy, the risks and benefits of these extensive procedures remain poorly defined.Methods:Prospectively collected data from patients operated on between January 1, 2014, and June 30, 2025, were analyzed. The primary endpoints included overall survival and recurrence-free survival. Secondary endpoints comprised radicality of resection and incidence of postoperative complications.Results:Of 58 consecutively operated patients, 52 underwent neoadjuvant oncologic treatment. Surgical procedures consisted of DP-CAR (n = 38), TP-CAR (n=11), and exploratory laparotomy (n=9). Uncomplicated preoperative hepatic artery embolization was achieved in 54 patients (93.1%). Pancreatic leaks occurred in 22.2% of cases, whereas organ ischemia was observed in 16.3%. R0 and R1 resection rates were 26.5% and 73.5%, respectively. Median overall survival for patients receiving neoadjuvant oncologic treatment followed by surgery, upfront surgery, and exploratory surgery was 28.0, 23.3, and 20.1 months, respectively. The median recurrence-free survival was 6.0 months (range: 1–43), whereas the median interval from surgery to detection of distant metastases or local recurrence was 5 (range: 1–43) and 13 months (range: 3–32), respectively (P < 0.005).Conclusion:DP-CAR and TP-CAR may be performed with complication rates comparable to standard distal and total pancreatectomies. Nonetheless, the elevated rate of cancer recurrence underscores the necessity of meticulous preoperative patient selection. INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) in the body and tail of the gland typically presents at an advanced, unresectable stage.1,2 Traditionally, invasion of the celiac axis (CA) and common hepatic artery (CHA) has precluded surgery due to high risks of ischemic complications and poor long-term survival. In selected patients where the gastroduodenal artery (GDA) is not infiltrated by tumor, distal or total pancreatectomy with celiac arterial resection (DP-CAR and TP-CAR), combined with splenectomy, may be considered. The DP-CAR approach necessitates reliance on compensatory blood flow from the superior mesenteric artery (SMA) via the pancreatoduodenal arcades and GDA through the proper hepatic artery to the liver, and retrograde perfusion through the left gastric artery (LGA) to the stomach, after division of the celiac axis supply. In contrast, TP-CAR relies on arterial reconstruction as the pancreatoduodenal arcades are removed. CAR with subtotal gastrectomy was first introduced by Appleby in 1953 for advanced gastric malignancies.3 Subsequent modifications for use in pancreatic body tumors focused on minimizing ischemic complications to the liver and stomach, achieved through either arterial reconstruction or preoperative hepatic artery embolization to increase collateral circulation.4,5 DP-CAR and TP-CAR may provide extended survival, and in select cases, potential cure for patients with otherwise poor prognoses. Outcomes have been further enhanced by the introduction of neoadjuvant oncologic therapy (NT).6–9 Nevertheless, the procedures remain associated with a significant rate of postoperative complications with prolonged hospitalization, especially due to organ ischemia, and recurrence rates also remain high.10–12 The aim of our study is to present our institutional results, assessing the roles of oncologic therapy, preoperative coiling, surgical complications, and a critical evaluation of the indications for DP-CAR/TP-CAR in the context of recurrence-free survival (RFS) and overall survival (OS) outcomes that have generally remained limited. Furthermore, we present a comprehensive review of the treatment results based upon previously published data. METHODS In Denmark (6 million inhabitants), pancreatic surgery is centralized to 4 centers. Pancreatic surgery with arterial resection is only performed at the Hepato–Pancreato–Biliary (HPB) unit at Copenhagen University Hospital, Rigshospitalet, which is a tertiary hospital for HPB surgery with an annual flow of more than 200 pancreatic operations. Preoperative staging included a triple-phase multidetector-row computed tomography (0 point before contrast, arterial phase, and portal venous phase) after pancreatic protocol, and if needed, supplementary magnetic resonance imaging (MRI), endoscopic ultrasonography, and positron emission tomography. All images were evaluated at our multidisciplinary video-assisted tumor conference (MDT) in the presence of surgeons, oncologists, and dedicated radiologists from the respective pancreatic centers. Evaluation between resectable, borderline resectable (BRPC), and locally advanced tumors (LAPC) was made according to the classification of Isaji et al13 Preoperative biopsies were confirmative of PDAC in all patients. Most patients considered as candidates for DP-CAR or TP-CAR underwent NT and preoperative arterial embolization of the tumor-involved branches from the CA. Oncologic Treatment Oncologic therapy was performed at 4 specialized units. The NT protocols included FOLFIRINOX, gemcitabine with nab-paclitaxel, or S1. A few patients also had immunotherapy with MRI-guided stereotactic body radiation in a medical trial. After radical surgery, patients were offered adjuvant oncologic therapy (AT) depending on performance. NT was usually administered for 4 to 6 months (4–6 series). After NT, a new evaluation at the MDT with an updated CT scan was performed, and if the tumor was resectable, that is, treatment response or stable disease, the patient was scheduled for operation. Preoperative Embolization Embolization was done 1 to 2 weeks before surgery. We followed our own algorithm14 to manage the hepatic arteries and left gastric artery with selective angiography and embolization via the femoral artery to increase collateral pathways for the liver and the stomach (Fig. 1). In patients with variant anatomy such as a CHA or a right hepatic artery (RHA) branching from the SMA, preoperative embolization was not undertaken if vessels were not in contact with the tumor. An Amplatzer plug type IV (Abbott Cardiovascular, Santa Clara, CA) was used in embolization of the CHA. The LGA was coiled using Nester micro coils (Cook Medical, Bloomington, IN) if preoperative imaging showed tumor involvement or the tumor extended below its base. Liver enzymes and standardized ratio of prothrombin time international normalized ratio were monitored, and the patient was discharged the day after the embolization. A CT scan with arterial phase was performed the day before surgery to ensure GDA patency with blood flow to the hepatic artery (Fig. 1). Common hepatic artery (CHA) embolization. A, Celiac angiography with catheter in CHA. B, Post-procedure angiography shows complete CHA occlusion. Surgical Procedure All operations were performed as an artery-first procedure. Biopsies were taken at the base of the celiac trunk and 2 cm distally. If frozen sections were without tumor cells, the procedure would continue. After trial clamping the CHA just before the GDA branch, the arterial blood flow to the liver—now exclusively via the GDA—was evaluated with intraoperative ultrasound. The LGA and the mesenteric vessels were dissected at the lower margin of the pancreas. The greater curvature of the stomach was dissected, sparing the gastroepiploic arcade, and the short gastric vessels were divided. A trial clamping of the CA with ultrasound assessment of the intrahepatic arterial flow and the flow in the gastric arcades was performed. If flow was acceptable, the pancreatic neck was divided at the level of the portomesenteric confluence. The CA and CHA were divided en bloc along with resection of the distal pancreas and spleen using radical antegrade modular pancreato-splenectomy technique.15 At the time of clamping of the liver arteries, continuous infusion of epoprostenol 2 ng/kg/min (Flolan, GlaxoSmithKline Pharma A/S, UK) was initiated and continued for 5 days. Epoprostenol is a potent pulmonary and systemic vasodilator but also reduces platelet aggregation.16 If DP-CAR was not possible due to invasion beyond the GDA and/or PHA, the patient could be eligible for a TP-CAR. This procedure would follow the same dissection as the DP-CAR but with reconstruction of the PHA with a free arterial donor graft to the aorta or common iliac artery. The remaining steps of the procedure followed a standard total pancreatectomy with hepatico-jejunostomy and gastro-jejunostomy. Thrombosis prophylaxis with LMW heparin, enoxaparin 40 mg q.d. (Klexane, Sanofi S.A., France), was started the evening before surgery and continued after infusion of Flolan was terminated until 4 weeks from the time of discharge, after which no further anticoagulation was given. Postoperative organ ischemia was evaluated daily from liver enzymes, white blood cell counts, and C-reactive protein, and the hepatic arterial blood flow was evaluated by Doppler ultrasound on the first postoperative day and on demand. Patients with suspected organ ischemia underwent acute CT angiography and gastroscopy. Data Data were collected from our prospectively maintained clinical database of pancreatic operations and from the electronic hospital medical record systems. During the course of this study, 1735 patients with PDAC underwent surgery, of whom 1390 had pancreatic resection, and 345 patients were explored, 135 due to unresectable LAD. Outcomes were recorded as postoperative complications, length of stay, 30- and 90-day assessed mortality, OS, and RFS. All patients who underwent surgery for adenocarcinoma were followed regularly for 2 years or until death, either in person or by phone. Clinical status, CA 19-9 levels, and CT scan results were routinely assessed throughout the follow-up. Statistics Data are presented as median and range, and categorical data as numbers and percentages. Analysis of contingency tables was performed by Fisher exact test. Data between subgroups were analyzed with the Mann–Whitney test and Wilkoxon test. The Kaplan–Meier method was used to estimate OS and RFS, and the log-rank test to examine the differences between curves. Statistical significance was considered as a 2-tailed P-value with P < 0.05 for all tests. Analysis was performed with GraphPad Prism software version 9.2.0 (GraphPad, La Jolla, CA). RESULTS Between January 2014 and June 30, 2025, 49 patients underwent pancreatic resection, and 9 patients were surgically explored after NT. Median follow-up was 29.2 (6.9–122.9) months; the last follow-up was December 31, 2025. Baseline characteristics are shown in Table 1. TABLE 1.Demographics and Preoperative Details of 49 Patients Operated With DP-CAR or TP-CAR for Adenocarcinoma, and 9 Patients Who Underwent Explorative Laparotomy (%)ResectionExplorationGender Male26 (53.1)4 (44.4) Female23 (46.9)5 (55.6)Age Median; range63; 47-7866; 46-69ASA 15 (10.2) 225 (51.0)4 (44.4) 319 (38.8)5 (55.6) 40BMI <18.510 18.5–24.9296 (66.6) >24.9103 (33.3)Charlson 0–110 (20.4)8 (88.9) 2–323 (46.9)1 (11.1) 4–1016 (32.7)Concomitant disease Heart18 (36.7)4 (44.4) Lung3 (6.1) Diabetes6 (12.3)4 (44.4)Current smoker23 (46.9)3 (33.3)Alcohol (> 7 U/week)6 (12.3)1 (11.1)ASA: American Society of Anesthesiologists. Demographics and Preoperative Details of 49 Patients Operated With DP-CAR or TP-CAR for Adenocarcinoma, and 9 Patients Who Underwent Explorative Laparotomy (%) ASA: American Society of Anesthesiologists. Neoadjuvant Oncologic Therapy Fifty-two patients (90.0%) received NT (Table 2); the median time from the start of NT to operation was 5.2 (1.3–13.0) months. The remaining 6 patients underwent upfront surgery. Five patients were operated on before they finished the NT due to severe side effects; all of them received full AT. NT ended no earlier than 2 weeks before surgery. TABLE 2.Oncologic Therapy in 49 Patients Treated With DP-CAR or TP-CAR. Patients in Postoperative Palliative Care Received Various Therapies Before Transitioning To Best Supportive CareNeoadjuvantAdjuvantPalliationN492624Folfirinox35104Gemcitabine + nab-paclitaxel4115Gemcitabine92Gemcitabine + S113Gemcitabine + capecitabine3Oxaliplatin + S11Radiation4Immuno therapy + radiation3*1†Immunotherapi1‡No oncologic therapy62319*Gemcitabine, nab-paclitaxel, ipilimumab, nivolumab, and stereotactic body radiation therapy.†Ipilimumab, nivolumab, tocilizumab, and stereotactic body radiation therapy.‡Gemcitabine, nab-paclitaxel, and pembrolizumab. Oncologic Therapy in 49 Patients Treated With DP-CAR or TP-CAR. Patients in Postoperative Palliative Care Received Various Therapies Before Transitioning To Best Supportive Care Gemcitabine, nab-paclitaxel, ipilimumab, nivolumab, and stereotactic body radiation therapy. Ipilimumab, nivolumab, tocilizumab, and stereotactic body radiation therapy. Gemcitabine, nab-paclitaxel, and pembrolizumab. The radiologic evaluation before operation compared with baseline showed tumor regression in 21 (40.4%) patients, progression in 3 patients (5.8%), and stable disease in 28 patients (53.9%). Tumor size before and after NT was 4.0 (1.4–9.6) and 3.5 (2.1–6.1) cm (P < 0.0001). Eleven patients had regression of tumor contact of a minimum of 1 artery, but only 1 tumor went from LAPC to BRPC. Regression of tumor contact to vessels was most common in the superior mesenteric vein (41.6%), followed by the SMA (31.3%), CA (16.3%), and CHA (2.7%). The final CT scan before surgery showed that there was tumor contact, either borderline or locally advanced, of the CHA in 67.2 % and the CA in 70.7% of the patients. Preoperative Embolization Fifty-four patients (93.1%) had preoperative arterial embolization, 53 of the CHA and 15 of the LGA, all procedures without complications, and no re-embolization was necessary. In 8 patients, the RHA branched off from the superior mesenteric artery but without tumor contact. In 1 patient, the CHA branched from the aorta. Only 2 patients (3.7%) had a minor elevation of transaminase after arterial embolization to 95 and 114 U/L, respectively (ref. female/male 10–45/10–70 U/L). Surgical Treatment and Complications All patients who had either DP-CAR or TP-CAR had resection of the celiac axis, and 6 patients in each group also had portomesenteric resection with end-to-end anastomosis (Table 3). Two patients with DP-CAR also had concomitant partial gastric resection. In 3 patients, where a planned DP-CAR could not be performed due to tumor ingrowth into the GDA, a TP-CAR with reconstruction of the arterial hepatic flow was made (graft between GDA and CHA; RHA to SMA; splenic artery to CHA). TABLE 3.Surgical Treatment and Number of Complications in 49 Patients Who Underwent DP-CAR and TP-CARSurgical TreatmentN (%)InterventionClavien-Dindo grade DP-CAR38* TP-CAR11 Porto-mesenterial resection12Patients with complications20 (40.1) Wound complications2 (4.1)OperationIIIb Pancreatric leak (POPF)10 (26.2)ConservativeII Intraabdominal absces7 (14.3)UL guided drainageIIIa Portal thrombosis/stenosis5 (10.2)4 Portal stentIIIb Liver infarction4 (8.2)ConservativeI Gastric ischemia3 (6.1)Gastric resectionIIIb Gallbladder ischemia1 (2.0)CholecystectomyIIIb Gastric bleeding1 (2.0)EndoscopicIIIb Liver abscess1 (2.0)UL guided drainageIIIa Multi organ failure2 (4.1)IVb Intensive care unit3 (6.1)IVbDGE None43 (87.8) Grade A6 (12.2) Grade B and C0Length of stay (days)13 (6–100) DP-CAR12 (6–100) TP-CAR15 (7–66)In-hospital mortality0*Two concomitant partial gastric resections. Surgical Treatment and Number of Complications in 49 Patients Who Underwent DP-CAR and TP-CAR Two concomitant partial gastric resections. Twenty patients (40.1%), who had pancreatic resection, developed 1 or more surgical complications. The most common complication was pancreatic leak (22.2%), organ ischemia (16.3 %), and intra-abdominal abscess formation (14.3%). One patient developed hypoinsulinemia after DP-CAR, and 2 patients developed treatment-refractory diarrhea. After resection of the TC, the postoperative level of transaminase increased in 30 patients (61.2%) to 404 (91–4820) U/L. Eight patients developed ischemic complications. Contrast-enhanced CT confirmed 4 liver infarctions. None of the patients developed liver failure, and all were treated conservatively. One patient had gallbladder necrosis, and 3 patients had ischemia of the stomach, 2 of them with perforation. All patients with gastric ischemia had preoperative embolization of the CHA, and 2 of the patients also had embolization of the LGA. One patient with liver infarction did not have preoperative embolization. Delayed gastric emptying, as assessed by the requirement for a nasogastric tube for more than 7 days with intolerance for oral intake, was not observed. In 43 patients, the tube was removed after a median of 2 days; 6 patients had removal within 4 to 7 days due to additional procedures or complications. No significant difference in gastric emptying was found between 15 patients who underwent LGA embolization (median 3 days, range 1–5 days) and 39 patients with LGA spared (median 2 days, range 1–6 days), P = 0.658. There were no in-hospital deaths, but one 90-day mortality occurred due to early recurrence with bowel obstruction from peritoneal carcinosis and demise 2 weeks after palliative surgery. Pathology On pathologic examination, all tumors were PDAC, as confirmed preoperatively. One patient also had a neuroendocrine incidentaloma of 13 mm with a Ki67 of 1%, and 2 patients had an IPMN unrelated to the carcinoma. In 12 resection specimens, tumor touched or encroached on the CA. However, histopathology showed actual arterial invasion in only 9 of all resection specimens (18.4%) (Table 4). Seven patients (53.9%) with R0 resection had at least 1 positive node. In 1 patient, no remnant tumor tissue was found after NT; however, the patient had liver metastases 3 months after the operation. TABLE 4.Pathologic Findings in 49 Resection Specimens (%)Tumor size, cm3.5 (0.0–9.3)T T0*1 (2.0) T15 (10.2) T216 (32.7) T318 (36.7) T49 (18.4)N N014 (28.6) N126 (53.0) N29 (18.4)M M047 (95.9) M1†2 (4.1)Stage 01 (2.0) 18 (16.3) 223 (47.0) 315 (30.6) 42 (4.1)Differentiation Low7 (14.3) Medium32 (65.3) High8 (16.3) Not classified2 (4.1)R R0‡13 (26.5) R1‡36 (73.5) Anterior site26 (53.0) Posterior site21 (42.9) Mesenteric vein§3 (37.5) Mesenteric artery§1 (12.5) R20Vascular invasion17 (34.7)Perineural invasion35 (71.4)Invasion of celiac artery9 (18.4)*Previously diagnosed cancer disappeared after oncological treatment.†M1: metastatic aortic lymph node 16.‡R0/R1: Tumor-free margin ≥ 1.0/< 1.0 mm distance to tumor.§Only applies to 8 TP-CAR procedures. Pathologic Findings in 49 Resection Specimens (%) Previously diagnosed cancer disappeared after oncological treatment. M1: metastatic aortic lymph node 16. R0/R1: Tumor-free margin ≥ 1.0/< 1.0 mm distance to tumor. Only applies to 8 TP-CAR procedures. Postoperative Oncologic Therapy Twenty-six patients (53.1%) received AT, whereas the rest either declined adjuvant treatment, had poor performance, or relapsed rapidly and began palliative care instead. Only 26.2% of the patients who had AT continued with the preoperative protocol; the remaining patients had gemcitabine in monotherapy or in combination with capecitabine, nab-paclitaxel, or S1 due to low performance. Recurrence was treated according to oncologic protocol or best supportive care. All patients who had exploratory laparotomy and 24 patients (55.8%) with recurrence continued with palliative oncologic treatment; the remaining patients had best supportive care. Postoperative Outcome The OS for all resected patients, measured from the time of surgery, was 23.1 months (Fig. 2a). NT recipients had an OS of 21.1 months from the time of surgery, and upfront surgery patients had 23.3 months (NS). For NT-treated patients, OS from treatment initiation was 28.0 months (Fig. 2b). Median survival was 24.0 months with AT after NT, compared to 13.2 months without AT (P < 0.013). A, Overall and recurrence-free survival for DP-CAR and TP-CAR patients, and overall survival after exploratory laparotomy for non-resectability. B, Comparison of overall and recurrence-free survival between neoadjuvant therapy (NT) and upfront surgery. C, Overall and recurrence-free survival following neoadjuvant therapy comparing adjuvant versus no adjuvant therapy (AT). Forty-three patients (87.8%) had recurrence, 25 (58.1%) within 6 months of the operation. Fifteen recurrences (34.9%) were local, 18 (41.9%) in the liver, 9 (20.9%) in the lungs, 3 (7.0%) in the spinal column, and 1 (2.3%) in the abdominal wall. Fourteen patients (32.6%) had recurrence at multiple sites, and 11 patients (25.6%) had carcinosis. Median time from operation to observation of distant metastases versus local recurrence was 5 (1–43) and 13 (3–32) months, respectively (P < 0.005). The overall RFS was 6.0 (1–43) months; patients with NT had 7.0 (1–43) months, and patients with upfront surgery 5.0 (2–12) months (NS). Patients who had AT after NT had an RFS of 11.0 months, versus 5.0 months for those without AT (P < 0.006). At the end of the study, 11 patients (22.5%) were still alive after radical surgery, 6 of them (12.3%) without recurrence. Three patients achieved RFS of 117, 117, and 121 months, and are regarded as cured. The other 3 patients currently have RFS durations of 5, 12, and 12 months. Nine patients underwent exploratory laparotomy: 6 had carcinosis, 2 had invasion of the superior mesenteric artery, and 1 patient had both carcinosis and liver metastases. OS from the start of NT was 20.1 months, with 6 patients (66.7%) deceased by study end. DISCUSSION Patients who have surgery for advanced pancreatic cancer with celiac axis (CA) resection are at the lower end of the scale in terms of complication-free and RFS. Single-center reports are often limited in number of patients; therefore, most reports are multicenter studies or meta-analyses. The largest multicenter study is Japanese, with 632 patients from 63 institutions over a span of more than 30 years, starting in 1987.17 In this research, high-volume centers for DP-CAR were units that performed at least 1 operation per year. As with most multicenter studies and meta-analyses, challenges include overlapping patient data, limited information on complications, NT, and AT, and cases where patients lacked current oncological treatments, because many were treated before 2015. In our presentation, 54 out of 58 patients had preoperative arterial coiling, and 49 patients subsequently underwent pancreatectomy with en bloc resection of the CA according to treatment protocols, remaining largely consistent because we started the procedure. Fifty-two patients received NT according to international recommendations at the time of treatment. Fewer than 20% of the operations were exploratory procedures, as most patients with unresectable tumors were excluded from surgical intervention at the MDT based on radiological assessments. Preoperative CT imaging identified LAPC or BRPC adjacent to the CA and its branches in 41 patients; however, pathological confirmation of vascular invasion was obtained in only 9 cases. This discrepancy underscores how radiological assessment may over-stage tumors involving major arteries, due to difficulties differentiating post-NT inflammation from neoplasia—occasionally resulting in inaccurate judgments regarding resectability.18,19 Consequently, we only refrained from surgery in patients where arterial invasion was unequivocal, leading to 9 exploratory procedures in which the tumors were ultimately deemed unresectable. We used embolization for planned CA resections, utilizing reconstruction only for inadequate liver flow, and did not find differences in complication rates between these procedures. The benefits of preoperative embolization before DP-CAR versus arterial reconstruction are still unclear due to limited evidence.9,20–25 Organ ischemia after arterial resection and embolization varies widely in the available studies, with a higher incidence of ischemia after embolization than after arterial reconstruction. The reported incidence of liver ischemia is between 2.4 and 17.7%, and ischemic gastropathy 4.4 and 19.0%.9,26,27 Ischemic complications of the stomach are more common after embolization than after arterial reconstruction. In our series, 16.3% of patients had ischemic complications, including 4 liver infarcts that extended hospital stays but were not fatal. Unlike gastric ischemia, liver ischemia typically follows a mild course and was managed conservatively. POPF was the most frequent surgical complication in our patients, occurring at the same rate as in standard distal pancreatectomy;12,25–30 other complications were rare. Although delayed gastric emptying is commonly reported, we did not encounter it.12,19,30 No significant difference in ventricular emptying was observed between patients who underwent embolization of the left gastric artery and those in whom the artery was preserved. Two patients had transient refractory diarrhea that was not due to malabsorption but altered transit time due to a lesion of nerve plexuses around the TC and CHA.27,30,31 Although there is an overweight of beta-cells in the body and tail of the pancreas,32 only 1 patient developed post-resection hypoinsulinemia. Overall, aside from ischemia, DP-CAR complications match those of standard distal pancreatectomy and do not pose a significant procedural risk. Our R0 resection rate was 26.5%, lower than previously reported ranges between 31% and 93%,8,16,25–28,33 and due to a close tumor margin to the anterior border or through growth in 51% of cases. No significant survival difference was observed between R0 and R1 resections, aligning with other studies.30,33,34 Notably, 71% of our patients had nodal metastases, higher than major meta-analyses,11,19,34 which may explain survival results. There is no consensus on neoadjuvant therapy duration before surgery.35 In our study, OS was 28 months after NT and surgery, with a median NT duration of 5 months. OS postsurgery was similar for patients who did not receive NT, but the sample size was limited. Starting NT provided a 5-month OS advantage over upfront surgery and 7 months over the explored group. AT after NT correlated with improved OS, although untreated patients’ poor postoperative status may have influenced these findings. Reported survival rates vary widely, with an OS between 15 to 25 months.6–11,25,26,28,30,34,36 Two Japanese cohorts achieving as high as 31 to 40 months, which was most likely due to the excellent S1 responsiveness in this population.17,34 However, it is difficult to relate to data because information about oncological treatment is insufficient or lacking in several reports. In 3 reports from USA and Europe with 76 patients receiving NT and 56 patients receiving either NT or AT, OS was 32, 25, and 18 months, respectively.6,8,9 RFS remains low in all reports, in our patients 6 months and in most studies under 10 months, thus a major part of patients will require ongoing oncological treatment or best supportive care after surgery until demise. Although recurrence rates for DP-CAR and TP-CAR in PDAC are high, these procedures may benefit appropriately selected patients over palliative care alone. As only about 25% of our patients in downstaging protocols proceed to surgery, surgical candidates may have more favorable disease characteristics independent of resection. To what extent oncologic treatment and surgery contribute to OS has been investigated; however, this was at a time when oncologic treatment was less effective than today. Three studies found an improvement in OS, chemotherapy alone vs. DP-CAR from 4.0 and 14.5 versus 12.2 and 20.8 months, respectively.36,37 These figures are expected to increase with improvement of oncologic treatment and set the indication for DP-CAR and TP-CAR. However, recurrence of pancreatic cancer is due to its biological behavior itself, as it has a poor response to chemotherapy,38 and survival also depends on the form of palliation that is given. The benefit of preoperative radiotherapy alongside induction chemotherapy for LAPC remains uncertain.39,40 SBRT is rarely used for downstaging or neoadjuvant therapy of LAPC and BRPC in Denmark, aligning with ESMO guidelines due to limited evidence.41 Nevertheless, 3 patients received protocolized MRI-guided SBRT as neoadjuvant therapy, and 5 patients received palliative radiation treatment; however, the small sample size prevents meaningful comparison with other oncological treatments. According to our national guidelines, MRI-guided SBRT can be offered as neoadjuvant treatment of LAPC after at least 2 months of chemotherapy if resection remains unfeasible. The limitations of this study are its retrospective design and the limited duration of follow-up for certain patients. Additionally, variations in AT are elements of uncertainty in the interpretation of survival outcomes. However, the present study included patients who in most cases were managed according to a standardized clinical protocol incorporating NT and preoperative coil embolization before DP-CAR or TP-CAR, all performed at a single-center. This ensured procedural consistency throughout the study period, which is critical for accurately evaluating outcomes. In contrast, multicenter studies often face greater uncertainty, particularly regarding surgical procedures and postoperative care, as standardization here is more challenging than according to oncological treatment protocols. CONCLUSION Except for treatable ischemic issues like liver ischemia, DP-CAR and TP-CAR have complication rates comparable to standard distal resections and total pancreatectomy. The choice between preoperative embolization and arterial reconstruction depends on surgical preference. Nevertheless, the rates of disease recurrence may represent a limitation and may, at least in part, reflect the presence of occult metastatic disease at the time of surgery in a proportion of patients. Consequently, treatment decisions should be individualized, with careful consideration of potential oncologic effects and treatment-related adverse effects, balanced against anticipated effects on patient quality of life. An ongoing challenge lies in the selection of patients who may be most likely to derive a clinically meaningful benefit from extended pancreatic resections.